Eton Pharmaceuticals Inc.

14.35
0.27 (1.92%)
At close: Apr 17, 2025, 3:59 PM
14.34
-0.07%
After-hours: Apr 17, 2025, 04:05 PM EDT
1.92%
Bid 13.84
Market Cap 384.83M
Revenue (ttm) 39.01M
Net Income (ttm) -3.82M
EPS (ttm) -0.15
PE Ratio (ttm) -95.67
Forward PE 11.76
Analyst Strong Buy
Ask 14.73
Volume 242,714
Avg. Volume (20D) 280,944
Open 14.16
Previous Close 14.08
Day's Range 13.60 - 14.46
52-Week Range 3.04 - 18.41
Beta 1.34

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezip...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2018
Employees 31
Stock Exchange NASDAQ
Ticker Symbol ETON
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $26, which is an increase of 81.18% from the latest price.

Stock Forecasts

Next Earnings Release

Eton Pharmaceuticals Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+10.78%
Eton Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription
5 months ago
+15.59%
Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results. HC Wainwright & Co. reiterated a Buy rating on the stock.